PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijmmLink to Publisher's site
 
Int J Mol Med. 2017 September; 40(3): 607–613.
Published online 2017 July 19. doi:  10.3892/ijmm.2017.3072
PMCID: PMC5548066

Dietary fiber in irritable bowel syndrome (Review)

Abstract

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder. It is widely believed that IBS is caused by a deficient intake of dietary fiber, and most physicians recommend that patients with IBS increase their intake of dietary fiber in order to relieve their symptoms. However, different types of dietary fiber exhibit marked differences in physical and chemical properties, and the associated health benefits are specific for each fiber type. Short-chain soluble and highly fermentable dietary fiber, such as oligosaccharides results in rapid gas production that can cause abdominal pain/discomfort, abdominal bloating/distension and flatulence in patients with IBS. By contrast, long-chain, intermediate viscous, soluble and moderately fermentable dietary fiber, such as psyllium results in a low gas production and the absence of the symptoms related to excessive gas production. The effects of type of fiber have been documented in the management of IBS, and it is known to improve the overall symptoms in patients with IBS. Dietary fiber acts on the gastrointestinal tract through several mechanisms, including increased fecal mass with mechanical stimulation/irritation of the colonic mucosa with increasing secretion and peristalsis, and the actions of fermentation byproducts, particularly short-chain fatty acids, on the intestinal microbiota, immune system and the neuroendocrine system of the gastrointestinal tract. Fiber supplementation, particularly psyllium, is both safe and effective in improving IBS symptoms globally. Dietary fiber also has other health benefits, such as lowering blood cholesterol levels, improving glycemic control and body weight management.

Keywords: microbiota, enteric nervous system, fermentation, immune system, intestinal endocrine cells, laxation, meteorism, psyllium

1. Introduction

Irritable bowel syndrome (IBS) is a chronic common gastrointestinal disorder with a prevalence of 10–20% among the adult population worldwide (115). The diagnosis of IBS is based mainly on symptom assessment using the Rome criteria (16,17). The cardinal symptom is abdominal discomfort/pain, which is associated with altered bowel habits and abdominal bloating/distension (1,4). Patients with IBS are divided into four subtypes according to the stool pattern: diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), mixed-diarrhea-and-constipation IBS (IBS-M) and unclassified IBS (16,17). Patients with IBS are usually diagnosed at a young age, and IBS is more common in women than in men (36,8,9,11, 12,14,15,18,19). Although IBS is not associated with increased mortality, it considerably reduces the quality of life (1,1921) and is an economic burden to society (22).

Dietary fiber includes non-digestible carbohydrates and the complex polymer, lignin, which are present in plants and have physiological effects in humans (23). Dietary fiber has long been used in the treatment of several gastrointestinal conditions (2438). It is widely believed that IBS is caused primarily by a deficient intake of dietary fiber (39). Increasing the dietary fiber intake has been the standard recommendation for patients with IBS (1). However, a systematic meta-analysis based on 12 small studies showed that increased dietary fiber consumption by patients with IBS did not improve IBS symptoms compared to placebo or a low-fiber diet (39). Other studies have shown that while consuming water-insoluble fiber does not improve IBS symptoms, consuming soluble fiber improves overall IBS symptoms (40,41). Subsequent studies have shone new light on fiber supplementation as a treatment for IBS. Several comprehensive reviews have been published recently on the role of dietary fibers in IBS (4246). The present review aimed to discuss the efficacy of fiber supplementation in the treatment of IBS, the type of dietary fiber that should be recommended, and the mechanisms underlying the effects of dietary fiber, particularly those concerning the interaction between fibers, microbiota, the immune system and the neuroendocrine regulatory system of the gut.

2. Types and characteristics of dietary fiber

Different types of dietary fiber are characterized by marked differences in physical and chemical structure, with the health benefits of dietary fiber being specific to each fiber type (23). Dietary fiber can be divided into soluble types (i.e., dissolving in water) and insoluble types based on their physical and chemical properties (47,48). Soluble dietary fiber can be subdivided into viscous (gel forming) and non-viscous (23,47). Dietary fiber can be divided further into short-chain and long-chain carbohydrates, and fermentable or non-fermentable types (4953). Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) are closely associated with the focus of this review, and are to be considered to be the short-chain carbohydrate, soluble, and highly fermentable type of dietary fiber.

Short-chain, soluble and highly fermentable dietary fiber (e.g., oligosaccharides) results in rapid gas production that can outpace the capacity of the gastrointestinal tract to absorb gas into the bloodstream for final elimination through the lungs. This imbalance can cause abdominal pain/discomfort, abdominal bloating/distension and flatulence (23,51,54). On the other hand, long-chain, intermediate viscous, soluble and moderately fermentable dietary fiber (e.g., psyllium) results in a low gas production and the absence of the symptoms related to excessive gas production (23,54,55).

3. Mechanisms of action of dietary fiber in IBS

Laxative effects

Insoluble dietary fiber increases fecal mass and accelerates colonic transit via mechanical stimulation/irritation of the colonic mucosa with increasing secretion and peristalsis (23,5663). Soluble dietary fiber is fermented by bacteria in the large intestine, which increases the stool bulk by increasing the biomass by fermentation byproducts, such as gas and short-chain fatty acids (61,62). The oro-anal transit time and sensation are affected by these changes and probably also through other effects on microbiota, immune cells, intestinal endocrine cell, enteric nervous system and permeability (6475) (Fig. 1). Soluble viscous dietary fiber (e.g., psyllium) is minimally fermented and forms a gel that is preserved during its passage through the large bowel and normalizes the stool form (26,7679).

Figure 1
Likely mechanisms through which dietary fiber affects the functions of the gastrointestinal tract. Dietary fiber acts as a prebiotic to intestinal microbiota that causes changes in their composition and induces the growth of beneficial bacteria. The intestinal ...

Interaction of dietary fiber with microbiota and the immune system

There is an increasing body of evidence to indicate that dietary fiber acts as a prebiotic that influences the composition of the intestinal microbiota (8088) (Fig. 1). Furthermore, the fermentation of dietary fiber byproducts, such as short-chain fatty acids (acetate, propionate and butyrate) and the decrease in luminal colonic pH promote the growth of beneficial bacteria, such as lactobacilli and bifidobacteria (8088).

Butyrate is one of the short-chain fatty acids that are produced by the fermentation of dietary fiber (23,54). Butyrate has been recently reported to suppress colonic inflammation in two ways: i) by inducing T-cell apoptosis, thus eliminating the source of inflammation, and ii) by suppressing interferon-γ (IFN-γ)-mediated inflammation (Fig. 1) (8991).

Interaction between dietary fiber and the neuroendocrine system (NES) of the gastrointestinal tract

The NES of the gastrointestinal tract comprises gastrointestinal endocrine cells and the enteric nervous system (Fig. 1). Various different types of endocrine cells are scattered between the epithelial cells of the mucosa (1,9297). These endocrine cells constitute approximately 1% of all epithelial cells in the gastrointestinal tract (92,93,98100) and they have specialized sensors in the form of microvilli that project into the lumen and respond to luminal stimuli by releasing hormones (101113). The distribution, functions and modes of action of the most important gastrointestinal endocrine cells have been described in detail elsewhere (95,114,115). Briefly, each cell type secretes one or more signaling substances into the lamina propria, where these substances act directly on nearby structures (autocrine/paracrine mode), indirectly via an endocrine mode of action (by circulating in the blood to reach distant targets), and/or through a synaptic mode of action (116). The enteric nervous system comprises two plexi: the submucosal plexus and myenteric plexus. The NES regulates several functions of the gastrointestinal tract, including sensation, motility, secretion, absorption, local immune defense and food intake (22,92,93,95,117). The components of the NES interact and integrate with each other, the autonomic nervous system, and the afferent and efferent nerve fibers of the central nervous system (22,95,117,118).

Dietary fiber appears to improve the global symptoms in patients with IBS, abdominal discomfort/pain, abdominal bloating/distension and altered bowel habit, probably by affecting the NES. Changes in the luminal intestinal pH and pressure can stimulate the release of the hormone serotonin, which is known to play a pivotal role in visceral sensitivity (95). The short-chain fatty acids produced by the fermentation of dietary fiber appear to affect several intestinal hormones, such as peptide YY (PYY) and glucagon-like peptide-1 (119122). PYY is known to stimulate the absorption of water and electrolytes, and regulate the 'ileal brake' (123128). Furthermore, PYY inhibits prostaglandin E2 and vasoactive intestinal polypeptide, which stimulate intestinal fluid secretion (129131). This can explain the effect of dietary fiber on gastrointestinal transit and secretion. It has recently been reported that changing from a typical Norwegian diet to a FODMAP-reduced diet is accompanied by changes in densities of the gastrointestinal endocrine cells in patients with IBS (132138). Since FODMAPs by definition constitute dietary fiber, these observations show that changing the dietary fiber intake is associated with changes in the gastrointestinal endocrine cells.

Short-chain fatty acids, particularly butyrate, produced by the fermentation of dietary fiber have been found to affect neurons of the enteric nervous system (119,139). Whether this is a direct effect on the enteric nervous system or involves indirect effects on the gastrointestinal endocrine cells remains to be determined.

4. Fiber supplementation in the treatment of IBS

Physicians (particularly those in the primary care system) usually recommend patients with IBS to increase their intake of dietary fiber to 20–35 g daily in order to regulate the stools and reduce abdominal pain and meteorism (140143). Supplementation with long-chain, intermediate viscous, soluble and moderately fermentable dietary fiber such as psyllium improves the global symptoms of IBS (26,144147). A recent meta-analysis that evaluated dietary fiber supplementation in 14 randomized controlled trials involving 906 patients with IBS found that fiber supplementation (especially with psyllium) was effective in improving global IBS symptoms compared to placebo (46).

Dietary fiber supplementation seems to be safe (46,147), although transient abdominal bloating/distention can occur if it is introduced too rapidly (23,148). Recommending fiber supplementation to patients with IBS is also inexpensive while having documented effects on IBS symptoms and other health benefits (23,147,149).

5. Conclusion

Dietary fiber affects the bowel habits through increasing the stool bulk with mechanical stimulation of the colonic mucosa. The fermentation of dietary fiber by intestinal microbiota lowers the luminal pH and has several byproducts, such as gas and short-chain fatty acids. The gas increases the luminal pressure while short-chain fatty acids, particularly butyrate, affect the NES and consequently affect gastrointestinal secretion and motility. Dietary fiber has additional health benefits such as lowering the blood cholesterol level, improving glycemic control, and body weight management (23,54,55).

The different types of dietary fiber exhibit marked differences in physical and chemical properties, and not all types of fiber are beneficial for patients with IBS. A general recommendation to increase fiber intake in this group of patients would be inappropriate since it could worsen the symptoms (39). Long-chain, intermediate viscous, soluble, and moderately fermentable dietary fiber (e.g., psyllium) has documented affects in the management of IBS, and can improve the overall symptoms of patients with IBS (23,41,46,51,54). Supplementation with this type of dietary fiber should be recommended to patients with all of the IBS subtypes, namely IBS-D, IBS-M, and IBS-C. When beginning a fiber supplementation regimen, a transient period of abdominal bloating/distension, discomfort, and change in the bowel habits may occur (150). Fiber supplementation should therefore be started gradually, with the intake increased by no more than 5 g/day each week (23).

Acknowledgments

The studies conducted by the authors and cited in this review were supported by grants from Helse-Vest, Norway (grant no. 911978), and Helse-Fonna Norway (grant no. 40415).

References

1. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers Inc.; New York, NY: 2012.
2. Thompson WG. A world view of IBS. In: Camilleri M, Spiller RC, editors. Irritable bowel syndrome. Saunders; Philadelphia and London: 2002. pp. 17–26.
3. Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology. 1995;109:671–680. doi: 10.1016/0016-5085(95)90373-9. [PubMed] [Cross Ref]
4. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: First population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47:225–235. doi: 10.1023/A:1013208713670. [PubMed] [Cross Ref]
5. Kennedy TM, Jones RH, Hungin AP, O'flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774. doi: 10.1136/gut.43.6.770. [PMC free article] [PubMed] [Cross Ref]
6. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastro-intestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580. doi: 10.1007/BF01303162. [PubMed] [Cross Ref]
7. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736–1741. doi: 10.1016/0016-5085(95)90738-6. [PubMed] [Cross Ref]
8. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: An international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–650. doi: 10.1046/j.1365-2036.2003.01456.x. [PubMed] [Cross Ref]
9. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304:87–90. doi: 10.1136/bmj.304.6819.87. [PMC free article] [PubMed] [Cross Ref]
10. Bordie AK. Functional disorders of the colon. J Indian Med Assoc. 1972;58:451–456. [PubMed]
11. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: A population-based study. J Gerontol A Biol Sci Med Sci. 1995;50:M184–M189. doi: 10.1093/gerona/50A.4.M184. [PubMed] [Cross Ref]
12. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991;100:998–1005. doi: 10.1016/0016-5085(91)90275-P. [PubMed] [Cross Ref]
13. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: A community survey. Br J Gen Pract. 2004;54:495–502. [PMC free article] [PubMed]
14. Quigley EM, Locke GR, Mueller-Lissner S, Paulo LG, Tytgat GN, Helfrich I, Schaefer E. Prevalence and management of abdominal cramping and pain: A multinational survey. Aliment Pharmacol Ther. 2006;24:411–419. doi: 10.1111/j.1365-2036.2006.02989.x. [PubMed] [Cross Ref]
15. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet. 1983;1:632–634. doi: 10.1016/S0140-6736(83)91802-0. [PubMed] [Cross Ref]
16. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, et al. Clinical Services Committee of The British Society of Gastroenterology Guidelines on the irritable bowel syndrome: Mechanisms and practical management. Gut. 2007;56:1770–1798. doi: 10.1136/gut.2007.119446. [PMC free article] [PubMed] [Cross Ref]
17. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. doi: 10.1053/j.gastro.2005.11.061. [PubMed] [Cross Ref]
18. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology. 1980;79:283–288. [PubMed]
19. Miller V, Whitaker K, Morris JA, Whorwell PJ. Gender and irritable bowel syndrome: The male connection. J Clin Gastroenterol. 2004;38:558–560. doi: 10.1097/00004836-200408000-00004. [PubMed] [Cross Ref]
20. Whitehead WE, Burnett CK, Cook EW, III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248–2253. doi: 10.1007/BF02071408. [PubMed] [Cross Ref]
21. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660. doi: 10.1053/gast.2000.16484. [PubMed] [Cross Ref]
22. El-Salhy M. Irritable bowel syndrome: Diagnosis and pathogenesis. World J Gastroenterol. 2012;18:5151–5163. [PMC free article] [PubMed]
23. Chutkan R, Fahey G, Wright WL, McRorie J. Viscous versus nonviscous soluble fiber supplements: Mechanisms and evidence for fiber-specific health benefits. J Am Acad Nurse Pract. 2012;24:476–487. doi: 10.1111/j.1745-7599.2012.00758.x. [PubMed] [Cross Ref]
24. Bouchoucha M, Faye A, Savarieau B, Arsac M. Effect of an oral bulking agent and a rectal laxative administered alone or in combination for the treatment of constipation. Gastroenterol Clin Biol. 2004;28:438–443. doi: 10.1016/S0399-8320(04)94953-6. [PubMed] [Cross Ref]
25. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: Systematic review. Am J Gastroenterol. 2005;100:936–971. doi: 10.1111/j.1572-0241.2005.40925.x. [PubMed] [Cross Ref]
26. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12:491–497. doi: 10.1046/j.1365-2036.1998.00336.x. [PubMed] [Cross Ref]
27. Mehmood MH, Aziz N, Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of psyllium husk (Ispaghula) in constipation and diarrhea. Dig Dis Sci. 2011;56:1460–1471. doi: 10.1007/s10620-010-1466-0. [PubMed] [Cross Ref]
28. Washington N, Harris M, Mussellwhite A, Spiller RC. Moderation of lactulose-induced diarrhea by psyllium: Effects on motility and fermentation. Am J Clin Nutr. 1998;67:317–321. [PubMed]
29. Wenzl HH, Fine KD, Schiller LR, Fordtran JS. Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology. 1995;108:1729–1738. doi: 10.1016/0016-5085(95)90134-5. [PubMed] [Cross Ref]
30. Qvitzau S, Matzen P, Madsen P. Treatment of chronic diarrhoea: Loperamide versus ispaghula husk and calcium. Scand J Gastroenterol. 1988;23:1237–1240. doi: 10.3109/00365528809090197. [PubMed] [Cross Ref]
31. Eherer AJ, Santa Ana CA, Porter J, Fordtran JS. Effect of psyllium, calcium polycarbophil, and wheat bran on secretory diarrhea induced by phenolphthalein. Gastroenterology. 1993;104:1007–1012. doi: 10.1016/0016-5085(93)90267-G. [PubMed] [Cross Ref]
32. Murphy J, Stacey D, Crook J, Thompson B, Panetta D. Testing control of radiation-induced diarrhea with a psyllium bulking agent: a pilot study. Can Oncol Nurs J. 2000;10:96–100. doi: 10.5737/1181912x10396100. [PubMed] [Cross Ref]
33. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30:908–914. doi: 10.1086/313826. [PubMed] [Cross Ref]
34. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González- Huix F, Riera J, González-Lara V, Domínguez-Abascal F, et al. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol. 1999;94:427–433. doi: 10.1111/j.1572-0241.1999.872_a.x. [PubMed] [Cross Ref]
35. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009;25:520–525. doi: 10.1016/j.nut.2008.11.017. [PubMed] [Cross Ref]
36. Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22:1199–1204. doi: 10.1111/j.1440-1746.2006.04535.x. [PubMed] [Cross Ref]
37. Smalley JR, Klish WJ, Campbell MA, Brown MR. Use of psyllium in the management of chronic nonspecific diarrhea of childhood. J Pediatr Gastroenterol Nutr. 1982;1:361–363. doi: 10.1097/00005176-198201030-00014. [PubMed] [Cross Ref]
38. Heather DJ, Howell L, Montana M, Howell M, Hill R. Effect of a bulk-forming cathartic on diarrhea in tube-fed patients. Heart Lung. 1991;20:409–413. [PubMed]
39. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ. 2008;337:a2313. doi: 10.1136/bmj.a2313. [PubMed] [Cross Ref]
40. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: Time for reappraisal. Lancet. 1994;344:39–40. doi: 10.1016/S0140-6736(94)91055-3. [PubMed] [Cross Ref]
41. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi: 10.1136/bmj.b3154. [PubMed] [Cross Ref]
42. Philpott H, Nandurkar S, Lubel J, Gibson PR. Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome. World J Gastroenterol. 2015;21:11379–11386. doi: 10.3748/wjg.v21.i40.11379. [PMC free article] [PubMed] [Cross Ref]
43. Nagarajan N, Morden A, Bischof D, King EA, Kosztowski M, Wick EC, Stein EM. The role of fiber supplementation in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1002–1010. doi: 10.1097/MEG.0000000000000425. [PubMed] [Cross Ref]
44. Rao SS, Yu S, Fedewa A. Systematic review: Dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–1270. doi: 10.1111/apt.13167. [PubMed] [Cross Ref]
45. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM, Task Force on the Management of Functional Bowel Disorders American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–26. doi: 10.1038/ajg.2014.187. quiz S27. [PubMed] [Cross Ref]
46. Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1367–1374. doi: 10.1038/ajg.2014.195. [PubMed] [Cross Ref]
47. Anderson JW, Baird P, Davis RH, Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. Nutr Rev. 2009;67:188–205. doi: 10.1111/j.1753-4887.2009.00189.x. [PubMed] [Cross Ref]
48. Dikeman CL, Fahey GC., Jr Viscosity as related to dietary fiber: A review. Crit Rev Food Sci Nutr. 2006;46:649–663. doi: 10.1080/10408390500511862. [PubMed] [Cross Ref]
49. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: A narrative review. J Am Diet Assoc. 2009;109:1204–1214. doi: 10.1016/j.jada.2009.04.012. [PubMed] [Cross Ref]
50. Chouinard LE. The role of psyllium fibre supplementation in treating irritable bowel syndrome. Can J Diet Pract Res. 2011;72:e107–114. doi: 10.3148/72.1.2011.48. [PubMed] [Cross Ref]
51. Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: The role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19:245–251. doi: 10.1111/j.0269-2813.2004.01862.x. [PubMed] [Cross Ref]
52. Biesiekierski JR, Rosella O, Rose R, Liels K, Barrett JS, Shepherd SJ, Gibson PR, Muir JG. Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet. 2011;24:154–176. doi: 10.1111/j.1365-277X.2010.01139.x. [PubMed] [Cross Ref]
53. Muir JG, Rose R, Rosella O, Liels K, Barrett JS, Shepherd SJ, Gibson PR. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC) J Agric Food Chem. 2009;57:554–565. doi: 10.1021/jf802700e. [PubMed] [Cross Ref]
54. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108:718–727. doi: 10.1038/ajg.2013.63. [PubMed] [Cross Ref]
55. McRorie J, Kesler J, Bishop L, Filloon T, Allgood G, Sutton M, Hunt T, Laurent A, Rudolph C. Effects of wheat bran and Olestra on objective measures of stool and subjective reports of GI symptoms. Am J Gastroenterol. 2000;95:1244–1252. doi: 10.1111/j.1572-0241.2000.02017.x. [PubMed] [Cross Ref]
56. Tomlin J, Read NW. Laxative properties of indigestible plastic particles. BMJ. 1988;297:1175–1176. doi: 10.1136/bmj.297.6657.1175. [PMC free article] [PubMed] [Cross Ref]
57. Riottot M, Sacquet E, Leprince C. Effect of wheat bran upon gastro-intestinal transit in germ-free and conventional rats. Digestion. 1984;29:37–41. doi: 10.1159/000199006. [PubMed] [Cross Ref]
58. Burkitt DP, Walker AR, Painter NS. Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet. 1972;2:1408–1412. doi: 10.1016/S0140-6736(72)92974-1. [PubMed] [Cross Ref]
59. Lewis SJ, Heaton KW. Roughage revisited: The effect on intestinal function of inert plastic particles of different sizes and shape. Dig Dis Sci. 1999;44:744–748. doi: 10.1023/A:1026613909403. [PubMed] [Cross Ref]
60. Lewis SJ, Heaton KW. The intestinal effects of bran-like plastic particles: Is the concept of 'roughage' valid after all? Eur J Gastroenterol Hepatol. 1997;9:553–557. doi: 10.1097/00042737-199706000-00001. [PubMed] [Cross Ref]
61. Stephen AM, Cummings JH. Mechanism of action of dietary fibre in the human colon. Nature. 1980;284:283–284. doi: 10.1038/284283a0. [PubMed] [Cross Ref]
62. Stephen AM, Cummings JH. Water holding by dietary fibre in vitro and its relationship to faecal bulking in man. Proc Nutr Soc. 1979;38:55A. [PubMed]
63. Cummings JH, Stephen AM. The role of dietary fibre in the human colon. Can Med Assoc J. 1980;123:1109–1114. [PMC free article] [PubMed]
64. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology. 2001;120:652–668. doi: 10.1053/gast.2001.21908. [PubMed] [Cross Ref]
65. Camilleri M, Katzka DA. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1075–G1084. doi: 10.1152/ajpgi.00537.2011. [PubMed] [Cross Ref]
66. Camilleri M, Heading RC, Thompson WG. Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1407–1430. doi: 10.1046/j.1365-2036.2002.01305.x. [PubMed] [Cross Ref]
67. Gonlachanvit S, Coleski R, Owyang C, Hasler W. Inhibitory actions of a high fibre diet on intestinal gas transit in healthy volunteers. Gut. 2004;53:1577–1582. doi: 10.1136/gut.2004.041632. [PMC free article] [PubMed] [Cross Ref]
68. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: The role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27:104–119. doi: 10.1111/j.1365-2036.2007.03562.x. [PubMed] [Cross Ref]
69. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, Brummer RJ. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr. 2009;28:88–93. doi: 10.1016/j.clnu.2008.11.002. [PubMed] [Cross Ref]
70. Hamer HM, Jonkers DM, Loof A, Vanhoutvin SA, Troost FJ, Venema K, Kodde A, Koek GH, Schipper RG, van Heerde WL, et al. Analyses of human colonic mucus obtained by an in vivo sampling technique. Dig Liver Dis. 2009;41:559–564. doi: 10.1016/j.dld.2008.12.100. [PubMed] [Cross Ref]
71. Hamer HM, Jonkers DM, Renes IB, Vanhoutvin SA, Kodde A, Troost FJ, Venema K, Brummer RJ. Butyrate enemas do not affect human colonic MUC2 and TFF3 expression. Eur J Gastroenterol Hepatol. 2010;22:1134–1140. doi: 10.1097/MEG.0b013e32833a6ca0. [PubMed] [Cross Ref]
72. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruïne A, Bast A, Venema K, Brummer RJ. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr. 2010;29:738–744. doi: 10.1016/j.clnu.2010.04.002. [PubMed] [Cross Ref]
73. Keszthelyi D, Troost FJ, Jonkers DM, Helyes Z, Hamer HM, Ludidi S, Vanhoutvin S, Venema K, Dekker J, Szolcsányi J, et al. Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: A role in pain symptom generation? Eur J Pain. 2013;17:1299–1306. doi: 10.1002/j.1532-2149.2013.00309.x. [PubMed] [Cross Ref]
74. Vanhoutvin SA, Troost FJ, Hamer HM, Lindsey PJ, Koek GH, Jonkers DM, Kodde A, Venema K, Brummer RJ. Butyrate-induced transcriptional changes in human colonic mucosa. PLoS One. 2009;4:e6759. doi: 10.1371/journal.pone.0006759. [PMC free article] [PubMed] [Cross Ref]
75. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DM, Venema K, Brummer RJ. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil. 2009;21:952–e76. doi: 10.1111/j.1365-2982.2009.01324.x. [PubMed] [Cross Ref]
76. McRorie J, Pepple S, Rudolph C. Effects of fiber laxatives and calcium docusate on regional water content and viscosity of digesta in the large intestine of the pig. Dig Dis Sci. 1998;43:738–745. doi: 10.1023/A:1018805812321. [PubMed] [Cross Ref]
77. Marlett JA, Fischer MH. The active fraction of psyllium seed husk. Proc Nutr Soc. 2003;62:207–209. doi: 10.1079/PNS2002201. [PubMed] [Cross Ref]
78. Marlett JA, Kajs TM, Fischer MH. An unfermented gel component of psyllium seed husk promotes laxation as a lubricant in humans. Am J Clin Nutr. 2000;72:784–789. [PubMed]
79. Fischer MH, Yu N, Gray GR, Ralph J, Anderson L, Marlett JA. The gel-forming polysaccharide of psyllium husk (Plantago ovata Forsk) Carbohydr Res. 2004;339:2009–2017. doi: 10.1016/j.carres.2004.05.023. [PubMed] [Cross Ref]
80. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutr Res Rev. 2004;17:259–275. doi: 10.1079/NRR200479. [PubMed] [Cross Ref]
81. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412. [PubMed]
82. Roberfroid M. Prebiotics: The concept revisited. J Nutr. 2007;137(Suppl 2):830S–837S. [PubMed]
83. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, et al. Prebiotic effects: Metabolic and health benefits. Br J Nutr. 2010;104(Suppl 2):S1–S63. doi: 10.1017/S0007114510003363. [PubMed] [Cross Ref]
84. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108:975–982. doi: 10.1016/0016-5085(95)90192-2. [PubMed] [Cross Ref]
85. Bouhnik Y, Flourié B, Riottot M, Bisetti N, Gailing MF, Guibert A, Bornet F, Rambaud JC. Effects of fructooligosaccharides ingestion on fecal bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans. Nutr Cancer. 1996;26:21–29. doi: 10.1080/01635589609514459. [PubMed] [Cross Ref]
86. Bouhnik Y, Raskine L, Simoneau G, Paineau D, Bornet F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. Nutr J. 2006;5:8. doi: 10.1186/1475-2891-5-8. [PMC free article] [PubMed] [Cross Ref]
87. Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, Marteau P, Flourié B, Bornet F, Rambaud JC. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr. 1999;129:113–116. [PubMed]
88. Kleessen B, Sykura B, Zunft HJ, Blaut M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr. 1997;65:1397–1402. [PubMed]
89. Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH, Liu K. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1405–G1415. doi: 10.1152/ajpgi.00543.2011. [PubMed] [Cross Ref]
90. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res. 2003;1:855–862. [PubMed]
91. Stempelj M, Kedinger M, Augenlicht L, Klampfer L. Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem. 2007;282:9797–9804. doi: 10.1074/jbc.M609426200. [PubMed] [Cross Ref]
92. May CL, Kaestner KH. Gut endocrine cell development. Mol Cell Endocrinol. 2010;323:70–75. doi: 10.1016/j.mce.2009.12.009. [PMC free article] [PubMed] [Cross Ref]
93. Gunawardene AR, Corfe BM, Staton CA. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol. 2011;92:219–231. doi: 10.1111/j.1365-2613.2011.00767.x. [PubMed] [Cross Ref]
94. El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG, Hausken T. The role of diet in the pathogenesis and management of irritable bowel syndrome (Review) Int J Mol Med. 2012;29:723–731. [PubMed]
95. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: The role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012;4:2783–2800. [PubMed]
96. Tanaka-Shintani M, Watanabe M. Immunohistochemical study of enterochromaffin-like cell in human gastric mucosa. Pathol Int. 2007;57:572–583. doi: 10.1111/j.1440-1827.2007.02141.x. [PubMed] [Cross Ref]
97. Lönroth H, Håkanson R, Lundell L, Sundler F. Histamine containing endocrine cells in the human stomach. Gut. 1990;31:383–388. doi: 10.1136/gut.31.4.383. [PMC free article] [PubMed] [Cross Ref]
98. Buffa R, Capella C, Fontana P, Usellini L, Solcia E. Types of endocrine cells in the human colon and rectum. Cell Tissue Res. 1978;192:227–240. doi: 10.1007/BF00220741. [PubMed] [Cross Ref]
99. Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: Development and differentiation of gut endocrine cells. Endocrinology. 2004;145:2639–2644. doi: 10.1210/en.2004-0051. [PubMed] [Cross Ref]
100. Sjölund K, Sandén G, Håkanson R, Sundler F. Endocrine cells in human intestine: An immunocytochemical study. Gastroenterology. 1983;85:1120–1130. [PubMed]
101. Sandström O, El-Salhy M. Ageing and endocrine cells of human duodenum. Mech Ageing Dev. 1999;108:39–48. doi: 10.1016/S0047-6374(98)00154-7. [PubMed] [Cross Ref]
102. El-Salhy M. Ghrelin in gastrointestinal diseases and disorders: A possible role in the pathophysiology and clinical implications (Review) Int J Mol Med. 2009;24:727–732. doi: 10.3892/ijmm_00000285. [PubMed] [Cross Ref]
103. Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients. Handb Exp Pharmacol. 2012;209:309–335. doi: 10.1007/978-3-642-24716-3_14. [PubMed] [Cross Ref]
104. Lee J, Cummings BP, Martin E, Sharp JW, Graham JL, Stanhope KL, Havel PJ, Raybould HE. Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2012;302:R657–R666. doi: 10.1152/ajpregu.00345.2011. [PubMed] [Cross Ref]
105. Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med. 2010;12:e1. doi: 10.1017/S146239940900132X. [PubMed] [Cross Ref]
106. Raybould HE. Nutrient sensing in the gastrointestinal tract: Possible role for nutrient transporters. J Physiol Biochem. 2008;64:349–356. doi: 10.1007/BF03174091. [PubMed] [Cross Ref]
107. San Gabriel A, Nakamura E, Uneyama H, Torii K. Taste, visceral information and exocrine reflexes with glutamate through umami receptors. J Med Invest. 2009;56(Suppl):209–217. doi: 10.2152/jmi.56.209. [PubMed] [Cross Ref]
108. Rudholm T, Wallin B, Theodorsson E, Näslund E, Hellström PM. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept. 2009;152:8–12. doi: 10.1016/j.regpep.2008.10.002. [PubMed] [Cross Ref]
109. Sternini C, Anselmi L, Rozengurt E. Enteroendocrine cells: A site of 'taste' in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes. 2008;15:73–78. doi: 10.1097/MED.0b013e3282f43a73. [PMC free article] [PubMed] [Cross Ref]
110. Sternini C. Taste receptors in the gastrointestinal tract. IV. Functional implications of bitter taste receptors in gastrointestinal chemosensing. Am J Physiol Gastrointest Liver Physiol. 2007;292:G457–G461. doi: 10.1152/ajpgi.00411.2006. [PubMed] [Cross Ref]
111. Buchan AM. Nutrient Tasting and Signaling Mechanisms in the Gut III. Endocrine cell recognition of luminal nutrients. Am J Physiol. 1999;277:G1103–G1107. [PubMed]
112. Montero-Hadjadje M, Elias S, Chevalier L, Benard M, Tanguy Y, Turquier V, Galas L, Yon L, Malagon MM, Driouich A, et al. Chromogranin A promotes peptide hormone sorting to mobile granules in constitutively and regulated secreting cells: Role of conserved N- and C-terminal peptides. J Biol Chem. 2009;284:12420–12431. doi: 10.1074/jbc.M805607200. [PMC free article] [PubMed] [Cross Ref]
113. Shooshtarizadeh P, Zhang D, Chich JF, Gasnier C, Schneider F, Haïkel Y, Aunis D, Metz-Boutigue MH. The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regul Pept. 2010;165:102–110. doi: 10.1016/j.regpep.2009.11.014. [PubMed] [Cross Ref]
114. El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG, Hausken T. Is irritable bowel syndrome an organic disorder? World J Gastroenterol. 2014;20:384–400. doi: 10.3748/wjg.v20.i2.384. [PMC free article] [PubMed] [Cross Ref]
115. El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T. Irritable bowel syndrome: Recent developments in diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol Hepatol. 2014;8:435–443. doi: 10.1586/17474124.2014.888952. [PubMed] [Cross Ref]
116. Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders. Endocrinol Metab Clin North Am. 2010;39:713–727. doi: 10.1016/j.ecl.2010.08.009. [PubMed] [Cross Ref]
117. Seim I, El-Salhy M, Hausken T, Gundersen D, Chopin L. Ghrelin and the brain-gut axis as a pharmacological target for appetite control. Curr Pharm Des. 2012;18:768–775. doi: 10.2174/138161212799277806. [PubMed] [Cross Ref]
118. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20:14–21. doi: 10.1097/MED.0b013e32835bc703. [PMC free article] [PubMed] [Cross Ref]
119. Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis. Adv Exp Med Biol. 2014;817:195–219. doi: 10.1007/978-1-4939-0897-4_9. [PMC free article] [PubMed] [Cross Ref]
120. Cani PD, Everard A, Duparc T. Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol. 2013;13:935–940. doi: 10.1016/j.coph.2013.09.008. [PubMed] [Cross Ref]
121. Everard A, Cani PD. Gut microbiota and GLP-1. Rev Endocr Metab Disord. 2014;15:189–196. doi: 10.1007/s11154-014-9288-6. [PubMed] [Cross Ref]
122. Arora T, Loo RL, Anastasovska J, Gibson GR, Tuohy KM, Sharma RK, Swann JR, Deaville ER, Sleeth ML, Thomas EL, et al. Differential effects of two fermentable carbohydrates on central appetite regulation and body composition. PLoS One. 2012;7:e43263. doi: 10.1371/journal.pone.0043263. [PMC free article] [PubMed] [Cross Ref]
123. Maljaars PW, Keszthelyi D, Masclee AA. An ileal brake-through? Am J Clin Nutr. 2010;92:467–468. doi: 10.3945/ajcn.2010.30180. [PubMed] [Cross Ref]
124. Van Citters GW, Lin HC. Ileal brake: Neuropeptidergic control of intestinal transit. Curr Gastroenterol Rep. 2006;8:367–373. doi: 10.1007/s11894-006-0021-9. [PubMed] [Cross Ref]
125. Lin HC, Zhao XT, Wang L, Wong H. Fat-induced ileal brake in the dog depends on peptide YY. Gastroenterology. 1996;110:1491–1495. doi: 10.1053/gast.1996.v110.pm8613054. [PubMed] [Cross Ref]
126. Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, Ruggeri E, Tosetti C, Poggioli G, Morselli Labate AM, Monetti N, et al. Fat-induced ileal brake in humans: A dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology. 1993;105:733–739. doi: 10.1016/0016-5085(93)90890-O. [PubMed] [Cross Ref]
127. Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk DB. Further characterisation of the 'ileal brake' reflex in man - effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut. 1988;29:1042–1051. doi: 10.1136/gut.29.8.1042. [PMC free article] [PubMed] [Cross Ref]
128. Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee YC, Bloom SR, Misiewicz JJ, Silk DB. The ileal brake - inhibition of jejunal motility after ileal fat perfusion in man. Gut. 1984;25:365–374. doi: 10.1136/gut.25.4.365. [PMC free article] [PubMed] [Cross Ref]
129. Goumain M, Voisin T, Lorinet AM, Ducroc R, Tsocas A, Rozé C, Rouet-Benzineb P, Herzog H, Balasubramaniam A, Laburthe M. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: Pharmacological evidence and molecular cloning. Mol Pharmacol. 2001;60:124–134. [PubMed]
130. Souli A, Chariot J, Voisin T, Presset O, Tsocas A, Balasubramaniam A, Laburthe M, Rozé C. Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides. 1997;18:551–557. doi: 10.1016/S0196-9781(97)00069-7. [PubMed] [Cross Ref]
131. Whang EE, Hines OJ, Reeve JR, Jr, Grandt D, Moser JA, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci. 1997;42:1121–1127. doi: 10.1023/A:1018869116284. [PubMed] [Cross Ref]
132. Mazzawi T, El-Salhy M. Changes in small intestinal chro-mogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance. Int J Mol Med. 2016;37:1247–1253. [PMC free article] [PubMed]
133. Mazzawi T, Gundersen D, Hausken T, El-Salhy M. Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome. Mol Med Rep. 2014;10:2322–2326. [PMC free article] [PubMed]
134. Mazzawi T, Gundersen D, Hausken T, El-Salhy M. Increased chromogranin A cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance. Gastroenterol Res Pract. 2015;2015:823897. doi: 10.1155/2015/823897. [PMC free article] [PubMed] [Cross Ref]
135. Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. Eur J Clin Nutr. 2015;69:519–524. doi: 10.1038/ejcn.2014.151. [PMC free article] [PubMed] [Cross Ref]
136. Mazzawi T, El-Salhy M. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Exp Biol Med. 2017;0:1–8. doi: 10.1177/1535370217699537. [PMC free article] [PubMed] [Cross Ref]
137. Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr. 2016;70:175–181. doi: 10.1038/ejcn.2015.191. [PMC free article] [PubMed] [Cross Ref]
138. Mazzawi T, El-Salhy M. Dietary guidance and ileal enteroendocrine cells in patients with irritable bowel syndrome. Exp Ther Med. 2016;12:1398–1404. [PMC free article] [PubMed]
139. Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP, Neunlist M. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology. 2010;138:1772–1782. doi: 10.1053/j.gastro.2010.01.053. [PubMed] [Cross Ref]
140. Bellini M, Gambaccini D, Salvadori S, Tosetti C, Urbano MT, Costa F, Monicelli P, Mumolo MG, Ricchiuti A, De Bortoli N, et al. Management of chronic constipation in general practice. Tech Coloproctol. 2014;18:543–549. [PubMed]
141. Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, Giannini EG, et al. Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag. 2015;11:691–703. doi: 10.2147/TCRM.S54298. [PMC free article] [PubMed] [Cross Ref]
142. Alaimo K, McDowell MA, Briefel RR, Bischof AM, Caughman CR, Loria CM, Johnson CL. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988–91. Adv Data. 1994;258:1–28. [PubMed]
143. Briefel RR, Sempos CT, McDowell MA, Chien S, Alaimo K. Dietary methods research in the third National Health and Nutrition Examination Survey: Underreporting of energy intake. Am J Clin Nutr. 1997;65(Suppl 4):1203S–1209S. [PubMed]
144. McRorie JW., Jr Evidence-based approach to fiber supplements and clinically meaningful health benefits, Part 2: What to look for and how to recommend an effective fiber therapy. Nutr Today. 2015;50:90–97. doi: 10.1097/NT.0000000000000089. [PMC free article] [PubMed] [Cross Ref]
145. McRorie JW., Jr Evidence-based approach to fiber supplements and clinically meaningful health benefits, Part 1: What to look for and how to recommend an effective fiber therapy. Nutr Today. 2015;50:82–89. doi: 10.1097/NT.0000000000000082. [PMC free article] [PubMed] [Cross Ref]
146. Rutten JM, Korterink JJ, Venmans LM, Benninga MA, Tabbers MM. Nonpharmacologic treatment of functional abdominal pain disorders: A systematic review. Pediatrics. 2015;135:522–535. doi: 10.1542/peds.2014-2123. [PubMed] [Cross Ref]
147. Shah SL, Lacy BE. Dietary interventions and irritable bowel dyndrome: A review of the evidence. Curr Gastroenterol Rep. 2016;18:41. doi: 10.1007/s11894-016-0517-x. [PubMed] [Cross Ref]
148. Ansari R, Attari F, Razjouyan H, Etemadi A, Amjadi H, Merat S, Malekzadeh R. Ulcerative colitis and irritable bowel syndrome: Relationships with quality of life. Eur J Gastroenterol Hepatol. 2008;20:46–50. doi: 10.1097/MEG.0b013e3282f16a62. [PubMed] [Cross Ref]
149. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: Systematic review and meta-analysis. Arch Intern Med. 2009;169:651–658. doi: 10.1001/archinternmed.2009.22. [PubMed] [Cross Ref]
150. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S5–S21. doi: 10.1111/j.1572-0241.2005.50613_2.x. [PubMed] [Cross Ref]

Articles from International Journal of Molecular Medicine are provided here courtesy of Spandidos Publications